| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| ln Vitro |
Etevritamab (5 μg/mL) specifically binds to CD3 and EGFRvIII in CHO cells expressing human or cynomolgus monkey EGFRvIII[1]. Etevritamab (0-1000 ng/mL; 48 h) induces T cell activation, cytokine (IFN-γ) release, and upregulates CD25 expression in a co-culture system containing U-251 MG/EGFRvIII glioblastoma cells and human or cynomolgus monkey peripheral blood mononuclear cells (PBMCs). It also effectively binds to cynomolgus monkey EGFRvIII and CD3, thereby promoting cell lysis[1]. Etevritamab (0-1000 ng/mL; 48 h) induces upregulation of CD25, a T cell activation marker, on CD4+ and CD8+ T cells and mediates the redirection lysis of U-251 MG cells through microvesicle transfer of EGFRvIII[1].
|
|---|---|
| ln Vivo |
Etevritamab (AMG-596) (0.1–0.5 mg/kg; intravenous injection; daily; for 16 consecutive days) significantly prolonged the survival of NOD/SCID mice carrying orthotopic EGFRvIII-expressing GBM tumors. At the end of the study (day 44), the survival rate was 73% in the 0.5 mg/kg dose group and 40% in the 0.1 mg/kg dose group [1].
|
| Cell Assay |
Cytotoxicity assay [1]
Cell Types: U-251 MG/EGFRvIII glioblastoma cells Tested Concentrations: 0-1000 ng/mL Incubation Duration: 48 hours Experimental Results: Effectively activated cynomolgus monkey EGFRvIII and CD3, promoting target cell lysis |
| Animal Protocol |
Animal/Disease Models:NOD.CB17-Prkdcscid/J (NOD/SCID) (6-week-old female mice, orthotopic xenograft model (U-87 MG/EGFRvIII tumor cells, 10⁵ cells/mouse)/subcutaneous xenograft model (U-251 MG/EGFRvIII tumor cells, 10⁷ cells/mouse)) [1]
Doses: 0.5 mg/kg; 0.1 mg/kg Route of Administration: Intravenous injection; once daily; for 11 and 16 consecutive days Experimental Results: Significantly prolonged survival. At the end of the study (day 44), the survival rate of the 0.5 mg/kg group was 73%, and the survival rate of the 0.1 mg/kg group was 40%. Histopathological analysis showed no obvious tumors. It induced significant antitumor activity, with an average tumor volume of 41 mm³ on day 22, compared to an average tumor volume of 568 mm³ in the vector control group mice. |
| References |
|
| CAS # |
2329692-74-0
|
|---|---|
| Related CAS # |
Protein A Agarose; HOLO Human Interleukin-2 (IL-2) Detection Kit; Bradford Protein Assay Kit; Cell Counting Kit-8
|
| Appearance |
Colorless to light yellow liquid
|
| Synonyms |
AMG-596
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
